Dramatic response to alectinib in an ALK‐positive LCNEC patient with a poor performance status: A case report

Dramatic response to alectinib in an ALK‐positive LCNEC patient with a poor performance status: A case report

Abstract The echinoderm microtubule‐associated protein‐like 4 (EML4)–anaplastic lymphoma kinase (ALK) fusion gene, a driver mutation in lung carcinoma, is fairly common in lung adenocarcinoma but rare in large cell neuroendocrine carcinoma (LCNEC). Here we report a case of stage IV LCNEC positive fo...

Full description

Bibliographic Details
Main Authors: Kazuki Masuda, Masafumi Saiki, So Shimamura, Shuichiro Ide, Yoshinori Uchida, Yusuke Sogami, Hiroshi Ishihara, Fumi Ikeda, Kiyotaka Kugiyama
Format: Article
Language:English
Published: Wiley 2021-09-01
Series:Respirology Case Reports
Subjects:
alectinib
echinoderm microtubule‐associated protein‐like 4‐anaplastic lymphoma kinase
large cell neuroendocrine carcinoma
poor performance status
Online Access:https://doi.org/10.1002/rcr2.817

Internet

https://doi.org/10.1002/rcr2.817

Similar Items